Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase I Clinical Study of GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

NCT05430373 is registered in ClinicalTrials.gov with Grit Biotechnology as lead sponsor.

NCT NCT05430373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05430373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase I Clinical Study of GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Lead sponsor
Grit Biotechnology
Phase
Phase 1
Overall status
Recruiting
Start date
May 23, 2022
Completion date
December 30, 2026
Enrollment
31 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors, adult